On gestagen treatment of advanced prostatic carcinoma

Scand J Urol Nephrol. 1978;12(2):119-21. doi: 10.3109/00365597809179977.

Abstract

Depostat treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study the clinical effect on prostatic cancer was, however, disappointing when compared to the well established effect of orchiectomy. The therapeutic failure of Depostat might be related to the incomplete suppression of plasma testosterone compared to that observed after orchiectomy.

Publication types

  • Comparative Study

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / therapy
  • Aged
  • Castration
  • Drug Evaluation
  • Gestonorone Caproate / administration & dosage
  • Gestonorone Caproate / adverse effects
  • Gestonorone Caproate / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / therapy
  • Testosterone / blood

Substances

  • Testosterone
  • Gestonorone Caproate